NoneNo Change
Adverse events incidence
Ertugliflozin → Adverse events incidence
Ertugliflozin → Adverse events incidence
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Ertugliflozin improves cardiac function in type 2 diabetes
Key finding
LVGLS improved from -15.5 ± 3.1% to -16.6 ± 2.8%, P = 0.004.
The study evaluated the effects of ertugliflozin on cardiac function in individuals with type 2 diabetes and pre-heart failure, finding significant improvements in certain cardiac metrics.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Some Concerns bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Ertugliflozin, Placebo
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
left ventricular global longitudinal strain (LVGLS)
Comparator
Placebo Group
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
The study evaluated the effects of ertugliflozin on cardiac function in individuals with type 2 diabetes and pre-heart failure, finding significant improvements in certain cardiac metrics.
Clinical relevance
These findings are clinically significant as they suggest that ertugliflozin may help improve heart function and manage diabetes in patients at risk of heart failure, potentially leading to better health outcomes. Understanding the impact of diabetes medications on heart health is crucial for optimizing treatment strategies in this vulnerable population.
Keep in mind
Some outcomes showed no significant changes. Effectiveness of ertugliflozin remains unclear for certain metrics. Study population may limit generalizability.
Published in
Journal Reference
Publication details and source links for this paper.
Soo L, Jae HB, Heran O, In-Chang H, Yeonyee EY, Goo-Yeong C. Ertugliflozin Improves Cardiac Function in Individuals with Type 2 Diabetes and Pre-Heart Failure. Cardiovascular Diabetology. 2024;23:373. doi:10.1186/s12933-024-02463-0
Save this study and add notes to your research library.
Main Effects
LVGLS improved from -15.5% to -16.6%, P = 0.004.
Significant reduction in HbA1c was observed.
Systolic blood pressure showed significant reduction.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Ertugliflozin and Adverse events incidence, Global longitudinal strain, HbA1c, and 9 more.
This study contributes evidence to
Primary intervention
Ertugliflozin
Primary outcomes
- Adverse events incidence
- Global longitudinal strain
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
12
Evidence pairs
12
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 59
1
Related topics
12
Evidence pairs
161
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 12 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongIncrease
angiotensin (1-7)
Ertugliflozin → angiotensin (1-7)
Ertugliflozin → angiotensin (1-7)
Evidence profile
StrongIncreaseClinical Outcomes
Unlock full evidence details
StrongIncrease
angiotensin-converting enzyme 2 (ACE2)
Ertugliflozin → angiotensin-converting enzyme 2 (ACE2)
Ertugliflozin → angiotensin-converting enzyme 2 (ACE2)
Evidence profile
StrongIncreaseClinical Outcomes
Unlock full evidence details
HarmfulDecrease
Global longitudinal strain
Ertugliflozin → Global longitudinal strain
Ertugliflozin → Global longitudinal strain
Evidence profile
HarmfulDecreaseClinical Outcomes
Unlock full evidence details
NoneDecrease
HbA1c
Ertugliflozin → HbA1c
Ertugliflozin → HbA1c
Evidence profile
NoneDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
Incidence of proteinuria
Ertugliflozin → Incidence of proteinuria
Ertugliflozin → Incidence of proteinuria
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
NoneIncrease
Left ventricular ejection fraction (LVEF)
Ertugliflozin → Left ventricular ejection fraction (LVEF)
Ertugliflozin → Left ventricular ejection fraction (LVEF)
Evidence profile
NoneIncreaseMetabolic Health
Unlock full evidence details
NoneDecrease
Left ventricular mass index
Ertugliflozin → Left ventricular mass index
Ertugliflozin → Left ventricular mass index
Evidence profile
NoneDecreaseMetabolic Health
Unlock full evidence details
StrongDecrease
lipoprotein(a)
Ertugliflozin → lipoprotein(a)
Ertugliflozin → lipoprotein(a)
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
NoneDecrease
NT-proBNP
Ertugliflozin → NT-proBNP
Ertugliflozin → NT-proBNP
Evidence profile
NoneDecreaseMetabolic Health
Unlock full evidence details
NoneDecrease
Systolic blood pressure
Ertugliflozin → Systolic blood pressure
Ertugliflozin → Systolic blood pressure
Evidence profile
NoneDecreaseMetabolic Health
Unlock full evidence details
NoneDecrease
Uric Acid
Ertugliflozin → Uric Acid
Ertugliflozin → Uric Acid
Evidence profile
NoneDecreaseMetabolic Health
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- LVGLS improved by 1.1% with P = 0.004.
- Significant reduction in HbA1c observed.
- Systolic blood pressure significantly reduced.
Who this applies to
- Adults with type 2 diabetes.
- Individuals at risk of pre-heart failure.
Keep in Mind
- Not all cardiac function metrics improved significantly.
- Study results may not apply to all populations with diabetes.
- Further research is needed to confirm findings.
Between the Lines
- Some outcomes showed no significant changes.
- Effectiveness of ertugliflozin remains unclear for certain metrics.
- Study population may limit generalizability.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Ertugliflozin and angiotensin (1-7), Ertugliflozin and angiotensin-converting enzyme 2 (ACE2).
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
angiotensin (1-7) Evidence Hub
All studies measuring angiotensin (1-7)
1 studies
outcome_hubMeasures angiotensin (1-7) as a key outcome.
angiotensin-converting enzyme 2 (ACE2) Evidence Hub
All studies measuring angiotensin-converting enzyme 2 (ACE2)
1 studies
outcome_hubMeasures angiotensin-converting enzyme 2 (ACE2) as a key outcome.
Ertugliflozin Evidence Hub
All studies on Ertugliflozin
1 studies
intervention_hubContributes to Ertugliflozin evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Ertugliflozin and angiotensin (1-7)
Intervention: ErtugliflozinOutcome: angiotensin (1-7)
1 results
All studies on Ertugliflozin and angiotensin-converting enzyme 2 (ACE2)
Intervention: ErtugliflozinOutcome: angiotensin-converting enzyme 2 (ACE2)
1 results
All studies on Ertugliflozin
Intervention: Ertugliflozin
1 results
All studies measuring angiotensin (1-7)
Outcome: angiotensin (1-7)
1 results
All studies measuring angiotensin-converting enzyme 2 (ACE2)
Outcome: angiotensin-converting enzyme 2 (ACE2)
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Ertugliflozin improve incidence of proteinuria?
Emerging Evidence
Ertugliflozin appears to improve Incidence of proteinuria.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Incidence of proteinuria
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Ertugliflozin improve angiotensin (1-7)?
Emerging Evidence
Ertugliflozin appears to improve angiotensin (1-7).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
angiotensin (1-7)
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Ertugliflozin improve angiotensin-converting enzyme 2 (ace2)?
Emerging Evidence
Ertugliflozin appears to improve angiotensin-converting enzyme 2 (ACE2).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
angiotensin-converting enzyme 2 (ACE2)
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Ertugliflozin improve lipoprotein(a)?
Emerging Evidence
Ertugliflozin appears to improve lipoprotein(a).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
lipoprotein(a)
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Triple combination therapy lowered HbA1c more than dual therapy in type 2 diabetesAI virtual trials match real trial results for GLP-1 vs insulin in type 2 diabetesHRS-7535 improves glycemic control in adults with type 2 diabetesNatural products may improve glycemic control in type 2 diabetesNewer diabetes drugs show stronger weight and blood sugar benefits in prediabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.